Search results | stroke


Stroke Partnering

The Stroke Partnering provides understanding and access to the stroke partnering deals and agreements entered into by the worlds leading healthcare companies


Current Agreements Deal Analysis Update : October 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in September 2014.

Current Agreements Deal Analysis Update : September 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in August 2014.

Lundbeck: Bravely battling brain diseases

Top 50 Pharma company Lundbeck is researching, developing and marketing medications for the treatment of brain diseases.

Dealtalk: ViroPharma Said to Hire Goldman Amid Sanofi Interest

According to dealtalk, ViroPharma began working with Goldman Sachs Group Inc. on a possible auction after fielding an unsolicited approach.

Daiichi Sankyo partnering: Partnering on promising products

Daiichi Sankyo is a global pharmaceutical company engaged in the research and development, manufacturing, and sale and marketing of innovative and generic drugs, vaccines, and over-the counter medicines

Biotech IPOs pick up in 2013

The tide may have started to turn for initial public offerings from U.S. biotechnology companies, as a rising stock market, low interest rates and a lack of market volatility entice investors to take on the high risk inherent in the sector.

Partnering with Pfizer: Collaborating to give hope

Pfizer is a top pharma company active in partnering, licensing and M&A in pharmaceuticals

Is big pharma GSK eyeing its collaborators as potential acquisition targets?

Glaxo, a big pharma company may find its next acquisition target in one of its partnering companies just like the U.K. drugmaker found the last two

Epsilon Imaging seeks $2 million for ultrasound speckle technology

A Midwest medical device startup is looking to raise $2 million for its computer aided diagnostic imaging technology that measures and visualizes tissue motion using ultrasound.

Boston Scientific saving cash for possible acquisitions, CFO Capello says

Boston Scientific will reserve most of the $1 billion in free cash it expects to generate in 2012 for acquisitions, with plans to use 25 percent to buy back shares, Chief Financial Officer Jeff Capello said.


Sorry, your search returned no results.


Athersys and Chugai announce pharma licensing deal for ischemic stroke

Athersys and Chugai Pharmaceutical have announced a partnership and pharma licensing agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan.

Dainippon Sumitomo and SanBio Collaborate on Cell Therapy for Stroke Recovery

Under the agreement, DSP has received an option for exclusive U.S. and Canadian marketing rights to SB623. SB623 is a promising cell therapy drug candidate being developed by SanBio for disabilities caused by stroke for which there are currently no effective therapies. SB623 is an allogeneic cell product, derived from bone marrow stromal cells isolated more »

Athersys and Chugai in Multistem cell therapy pact

Athersys and Chugai Pharmaceutical have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan

University of Colorado in the pharma news with heavy funding

Pharma news: University of Colorado faculty researchers attracted $861.04 million in research awards in the 2013-14 fiscal year, based on preliminary figures.

Pharma Alliances between Regulus Therapeutics and AstraZeneca

Regulus Therapeutics announced the selection of an undisclosed oncology target by AstraZeneca under the pharma strategic alliances to discover, develop, and commercialize microRNA therapeutics.

Boehringer Ingelheim pharma partners Brigham and Women’s Hospital

Boehringer Ingelheim announced a multi-year pharma partners agreement with Brigham and Women’s Hospital.

AstraZeneca & Fudan Univ collaborate in pharma partnering deal on cardiovascular disease

AstraZeneca, a big pharma company has ventured in a pharma partnering pact with Fundan Univ.

M&A Deals: Bayer acquires Schiff Nutrition International for an agreed $1.2 billion

Germany’s Bayer, a top name in the pharma circle is set buy U.S. vitamins maker Schiff Nutrition International for an agreed $1.2 billion in a m&a agreement,  as it seeks stable sources of growth to complement its more volatile prescription drugs business

Big Pharma Boehringer Ingelheim resolves allegations against improper promotion of Aggrenox

Boehringer Ingelheim Pharmaceuticals, a top big pharma company,  has agreed to pay $95 million to resolve allegations relating to the improper promotion of the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease (COPD) drugs Atrovent and Combivent, and the hypertension drug Micardis, the Justice Department announced today

Singulex pulls a biotech IPO worth $86 million

In a biotech IPO undertaking, Singulex is offering as much as $86.25 million, with a promise to test to measure signs of heart disease at previously undetectable levels